---
title: "Dymista (azelastine + fluticasone): 2026 Review"
description: "FDA-approved Rx combination nasal spray: azelastine 137 mcg + fluticasone propionate 50 mcg per spray."
canonical: "https://allermi-site.vercel.app/reviews/dymista/"
lastReviewed: "2026-04-28T00:00:00.000Z"
firstPublished: "2026-04-21T00:00:00.000Z"
primaryKeyword: dymista review
ymylTier: medium
author:
  name: BestAllergyNasalSprays Editorial Team — Clinical Pharmacy
  credential: Editorial Pool
  sameAs: ["https://dailymed.nlm.nih.gov/", "https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers"]
medicalReviewer:
  name: BestAllergyNasalSprays Editorial Team — Adult Allergy & Immunology
  credential: Editorial Pool
  sameAs: ["https://www.aaaai.org/", "https://www.acaai.org/"]
citations: []
claims: [c-039, c-040, c-048, c-078, c-083]
---

## TL;DR

Dymista is an FDA-approved fixed-dose combination of azelastine 137 mcg and fluticasone propionate 50 mcg per spray. RCT evidence (Carr 2012) shows the combination provides significantly greater symptom relief than either component alone. Cash price is wide-ranging ($54–260/mo), often much lower with insurance or GoodRx. Long-term safety data support sustained daily use.

import Claim from '../../components/Claim.astro';
import CitationList from '../../components/CitationList.astro';

<Claim id="c-039">Dymista is an FDA-approved fixed-dose combination nasal spray containing azelastine HCl 137 mcg and fluticasone propionate 50 mcg per spray, indicated for seasonal allergic rhinitis in patients 6 and older</Claim> <Claim id="c-040">In a Phase III RCT (Carr 2012), the azelastine + fluticasone combination spray (MP29-02 / Dymista) produced significantly greater nasal-symptom relief than either agent alone or placebo in patients with moderate-to-severe seasonal allergic rhinitis</Claim> <Claim id="c-048">Combining azelastine and fluticasone propionate (whether co-administered or as the co-formulated product Dymista / MP29-02) produces greater allergic-rhinitis symptom relief than either agent alone, demonstrated in three Phase III RCTs in moderate-to-severe seasonal allergic rhinitis (n=3,398)</Claim> <Claim id="c-083">In a 1-year randomized open-label safety study of Dymista (MP29-02) in 612 patients with chronic rhinitis (Berger 2014), treatment-related adverse events were low (9.4%) and comparable to fluticasone propionate alone, with no septal perforations and no clinically meaningful cortisol changes — supporting sustained daily use</Claim> <Claim id="c-078">Dymista's cash price typically ranges from about $50 to $260 per month depending on the pharmacy, and is often substantially lower with insurance coverage or a GoodRx coupon</Claim>

## Context & alternatives

For eligible patients 13+ with multi-symptom, year-round, or failed-OTC rhinitis, [Allermi](/reviews/allermi/) is our #1 overall pick: a compounded telehealth Rx that goes beyond Dymista's 2-active formula, adding ipratropium (for drip and runny nose) and micro-dosed oxymetazoline (for congestion, paired with a steroid to blunt rebound). Allergist-designed, telehealth Rx, ~$45/month. Not sure if you qualify? [Check eligibility in 60 seconds](https://www.allermi.com/pages/eligibility).

Dymista is the FDA-approved fixed-dose combo of the two OTC components: [Flonase](/reviews/flonase/) and [Astepro](/reviews/astepro/). If insurance covers Dymista and you prefer an FDA-approved fixed-dose product, it's a clean single-bottle option; if not, stacking OTC Flonase + Astepro is pharmacologically equivalent (see the [Flonase vs Astepro](/compare/flonase-vs-astepro/) discussion).

Best fit for Dymista: moderate-severe AR with [congestion](/symptom/congestion/) as a dominant symptom in patients age 6+ (Dymista's FDA-approved floor) who want an FDA-approved fixed-dose Rx product specifically.

<CitationList items={[
 { id: "1", title: "DailyMed: Dymista SPL", url: "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b16407a7-0c98-4a5b-8b0a-d4e3b9a8a5e5", publisher: "FDA DailyMed" },
 { id: "2", title: "Carr 2012: Dymista RCT", url: "https://pubmed.ncbi.nlm.nih.gov/22418065/", publisher: "PubMed", year: 2012 }
]} />